CAR-T biotech Caribou weighs its options after struggling to find funding

Caribou Biosciences is discontinuing two allogeneic CAR-T cell therapy programs, including vispa-cel for relapsed or refractory B-cell non-Hodgkin lymphoma, due to a lack of funding. The California-based biotech had been working with the FDA to finalize the design of a Phase 3 trial for one of its therapies, but was unable to secure the necessary funds to proceed, according to STAT News.

The company's CEO, Rachel Haurwitz, cited the difficulty in raising money to fund the study as the reason for the shutdown. Caribou Biosciences was founded based on research from CRISPR scientist and Nobel laureate Jennifer Doudna.

Caribou Biosciences is effectively shutting down after failing to raise the required funds.

Brief written by urgent.news from Endpoints News, STAT News — 2 reports on this story. Machine-written — may contain errors; check the original before relying on it.